Bone's material flaws lead to disease
The weak tendons and fragile bones characteristic of osteogenesis imperfecta, or brittle bone disease, stem from a genetic mutation that causes the incorrect substitution of a single amino acid in the chain of thousands of amino acids making up a collagen molecule, the basic building block of bone and tendon.
According to researchers at MIT, that minuscule encoding error creates a defective collagen molecule that, at the site of the amino acid substitution, repels rather than attracts the collagen molecule alongside it. This creates a tiny rift in the tissue, which when repeated in many molecules, leads to brittle tissue, broken bones, deformity and, in the most severe form of the disease, death. For example, if healthy collagen tissue looked like a sheet of paper, diseased collagen tissue would look more like a sheet of paper full of tiny perforations. At each of these perforations, the sheet would be considerably more prone to tearing.
In what may be the first detailed molecular-based multi-scale analysis of the role of a materials' failure in human disease, a paper in Biophysical Journal describes exactly how the substituted amino acid repels other amino acids rather than forming chemical bonds with them, creating a radically altered structure at the nanoscale that results in severely compromised tissue at the macroscale. This approach to the study of disease, referred to as "materiomics" by the lead researcher on the project, Professor Markus Buehler of MIT's Department of Civil and Environmental Engineering, could prove valuable in the study of other diseases — particularly collagen- and other protein-based diseases — where a material's behavior and breakdown play a critical role.
"The consideration of how material properties change in diseases could lead to a new paradigm in the study of genetic disorders that expands beyond the biochemical approach," said Buehler.
"We wanted to see how a single-point genetic mutation in a collagen molecule could cause entire tissue to become brittle, soft and even fail. The medical community finds correlations between genetics and patients; our interest is in finding the correlation between genetics and a material's behavior," he said.
In new research, Buehler and Sebastian Uzel, a graduate student at MIT, and Alfonso Gautieri, Alberto Redaelli and Simone Vesentini of Politecnico di Milano modeled type I collagen's behavior at the atomistic level all the way up to the scale of the fibrils that make up whole tissue. The different forms of severity in brittle bone disease correlate with a particular genetic mutation; some amino acid substitutions for glycine create more severe forms of osteogenesis imperfecta.
Most read news
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Zeiss strenghtens in-house quality and production management
Creabilis Raises €15M in Series B Fundraising Round
Biocitech life science park boosts scientific score in 2008 - Biocitech residents further improve performance with 34 patents applied for, six new proofs of concept, seven pre-clinical trials and two clinical trials under way, 18 major scientific advances and a wide range of publications and scientific presentations
Neupro approved in Japan for Parkinson’s disease and Restless Legs Syndrome
Intercell announces start of pivotal Phase II/III study in India for vaccine to protect children from Japanese Encephalitis
Quotient Clinical and Bend Research Announce Collaboration To Accelerate Advancement of New Medicines

Taking aim at skin bacteria - Enzyme treatment of skin samples improves microbiome analysis

SeaBeLife awarded over €1.5 million in i-Nov innovation competition - Funding for company’s SeaBeEYE project will be used to develop new therapeutic approach for geographic atrophy – advanced form of dry AMD
Autifony Therapeutics announces initiation of Phase IIa study for first-in-class drug to treat tinnitus
